News
Windward Bio catches $175m from its IPO
Swiss biotech Windward Bio has raised $175m in its Nasdaq IPO as it prepares to take on some heavyweight rivals with its long-acting TSLP inhibitor.
News
Neurosterix' $105m round leads the week's biotech financings
Neurosterix raises $105m for its schizophrenia candidate, as Delix, VectorY, and Eli Radiopharma also add to their cash reserves.
R&D
Life sciences real estate: Beyond labs
Growth in biotechnology, pharmaceutical R&D, and advanced therapies is driving demand for specialist laboratory space.
R&D
Inspection readiness is now a commercial question
Manufacturers of advanced therapies are discovering that a digital quality system does more than satisfy inspectors.
News
BMS shakes up R&D under CMO Cristian Massacesi
Bristol Myers Squibb is combining its R&D operations into a single unit led by chief medical officer and development head Cristian Massacesi.
Debates & Insights
News
Press Releases
Editor's Picks
Editor's Picks
